Key facts
- Lymphatica Medtech’s last known valuation is $36.4M.
- It has raised $37.0M; the latest was Later Stage VC ($19.8M) in Oct 2024.
- Notable investors include MassChallenge, MedTech Innovator, Venture Kick, CDP Venture Capital (Rome), High-Tech Gründerfonds — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Lymphatica Medtech
- ·The full record, as it builds
Funding rounds
No funding rounds for Lymphatica Medtech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lymphatica Medtech
Developer of implantable devices designed to re-establish lymphatic circulation in individuals affected by lymphedema. The company produces the first active implantable lymphatic bypass, consisting of an implanted magnetically controlled micropump and catheters that internally drain the lymphatic fluid from multiple points in the affected limb, enabling patients with an effective remedy for lymphedema.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2016
- Employees
- 16
- Website
- lymphaticamedtech.com/
- Ownership
- Privately Held (backing)
Lymphatica Medtech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lymphatica Medtech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lymphatica Medtech in its N-PORT filings yet. We sweep new filings monthly.